Zeltia S.A.

https://www.zeltia.com

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marinebased drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments. *

	Start	1985-01-01 existent
	End	2015-11-02 reorganised
	Group	PharmaMar (Group)
	Today	PharmaMar S.A. (MSE: PHM)
	Successor	PharmaMar S.A. (MSE: PHM)
	Industry	CHEMICALS
	Industry 2	Yondelis®
	Person	Fernandéz Sousa-Faro, José María (Zeltia 201411 Chairman of Zeltia + PharmaMar)
	Person 2	de Francia, Luisa (Zeltia 201207 CFO)

	Region	Madrid
	Country	Spain (España)
	City	n. a. Madrid
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	178,100,000 (revenue, total, consolidated (2014) 2014-12-31)
	Profit	13,100,000 (2014-12-31)

		* Document for »About Section«:

		Record changed: 2023-06-26